ReviewBritish journal of pharmacology2011
β(2) -adrenoceptor agonists: current and future direction.
Review in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Pooled it
- Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.The Cochrane database of systematic reviews · 2014Pooled it
- Trial
- Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.BMC pulmonary medicine · 2016Trial
- Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.Respiratory research · 2015Trial
- Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.BMC pulmonary medicine · 2014Trial
- Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.International journal of chronic obstructive pulmonary disease · 2013Trial
- Trial
- Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management.Respiratory research · 2025Article
- Calmodulin Triggers Activity-Dependent rRNA Biogenesis via Interaction with DDX21.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Stability-indicating UPLC assay coupled with mass spectrometry for the analysis of vilanterol degradation products in human urine.Scientific reports · 2024Article
- Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease.Parkinsonism & related disorders · 2023Article
- Activity Map and Transition Pathways of G Protein-Coupled Receptor Revealed by Machine Learning.Journal of chemical information and modeling · 2023Article
- Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.Pharmacology research & perspectives · 2022Article
- Review of potential medical treatments for middle ear cholesteatoma.Cell communication and signaling : CCS · 2022Review
- The Challenges of Predicting Drug-Induced QTc Prolongation in Humans.Toxicological sciences : an official journal of the Society of Toxicology · 2022Review
- An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation fromEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-ActingMolecular pharmacology · 2021Article
- Activation of βArchives of pharmacal research · 2021Review
- Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts.ERJ open research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the passionate debate over the use of β(2) -adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD. A variety of β(2) -adrenoceptor agonists with long half-lives, also called ultra long-acting β(2) -adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achieving once-daily dosing. It is likely that the once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes. As combination therapy with an inhaled corticosteroid (ICS) and a LABA is important for treating patients suffering from asthma, and a combination with an inhaled long-acting antimuscarinic agent (LAMA) is important for treating COPD patients whose conditions are not sufficiently controlled by monotherapy with a β(2) -adrenoceptor agonist, some novel once-daily combinations of LABAs and ICSs or LAMAs are under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.